AstraZeneca Neuroscience selects ePharmaSolutions to manage clinical trials
iMed will leverage IT solutions to share and manage complex data with clinical trial investigators and other external partners on a common portal. AZ NS iMed vice president
iMed will leverage IT solutions to share and manage complex data with clinical trial investigators and other external partners on a common portal. AZ NS iMed vice president
Expected to be set up within a year, the new pharmaceutical technology centre will focus on drug discovery, process development and commercialization, drug characterization, drug delivery and diagnostics.
Covering areas like physical sciences, medical research, advanced materials, pharmaceutical manufacturing and advanced manufacturing, the projects focus on challenges such as developing new treatments for cancer and ensuring
Besides collaborating on three cancer targets, AstraZeneca is also developing two antisense drugs, ISIS-AR and ISIS-STAT3 discovered by Isis. AstraZeneca had acquired license for the two antisense drugs
Packaging of the bottle does not comply with the requirements of the Poison Prevention Packaging Act. The dietary supplement bottles contain 90 tablets of 25mg iron supplement each,
As per the definitive agreement signed between both the parties, AstraZeneca will acquire Pearl’s shares for initial consideration of $560m that is payable on completion of the transaction.
The approval will allow the use of Rienso in all adult iron deficiency anemia patients who cannot take oral iron, in addition to current indication for the treatment
Around 600 patients are expected be enrolled in the study and will be randomized with PB272 plus Xeloda or Tykerb plus Xeloda. Puma Biotechnology chief executive officer and
Pharmavite chief operating officer Mark Walsh said, "At 330,000 square feet, the Opelika-based Pharmavite facility is one of the largest vitamin, mineral and supplement (VMS) manufacturing facilities built
Conducted in 56 patients with hypercholesterolemia and a history of intolerance to two or more statins, the study demonstrated considerable tolerability profile of the investigational candidate. Following an